Lannett’s insulin glargine biosimilar candidate will break new ground as it moves through the 351(k) review pathway, according to Ha Kung Wong, an intellectual property law attorney with Venable of New York.
Based on an announcement last week, the longtime generics manufacturer Lannett would become among the first to file for insulin glargine product approval under the 351(k) Biologics License Application pathway.
Lannett’s progress through the 351(k) review process will be interesting to observe, said Ha Kung Wong, an intellectual property law attorney with Venable of New York.
Insulin products have previously tended to be approved under the 505(b)(2) pathway, under which applicants have had to do clinical studies to gain approval. Two phase 3 studies were done for Basalgar, Wong noted. So, it will be interesting to see whether the clinical testing requirements for Lannett’s insulin glargine candidate under 351(k) are as rigorous or less so, he said.
It will also be interesting to see whether or how easily Lannett’s insulin glargine obtains “interchangeable status,” which would mean pharmacists could decide on their own whether to fill prescriptions with this or Lantus. Much depends on the extent FDA’s interchangeability standards actually differ under the 351(k) pathway in practice for follow-on insulin products versus for other biosimilars, Wong said.
“Interchangeability status will give the follow-on insulin automatic substitution, depending on the state, at the pharmacy level, something that follow-on insulin via the 505(b)(2) pathway did not have access to. However, we know that interchangeability status typically requires additional testing,” he said.
He added that pursuant to the FDA’s guidance, if a biosimilar candidate under the 351(k) pathway passes a highly rigorous analytical assessment of biosimilarity to the reference product, an immunogenicity or “switching” study might not be required, assuming all other conditions are met. “Possibly, interchangeable status comes essentially automatically with biosimilar status for some follow-on insulins, which would make the 351(k) potentially more beneficial for those manufacturers,” Wong said, so this will be closely watched, too.
Besides a 505(b)(2) application, the other former route to approval for a follow-on insulin product was an Abbreviated New Drug Application, which unlike the 505(b)(2) pathway, offered the potential for 6 months of marketing exclusivity for the first filer approved as a generic.
The current guidelines on interchangeability indicate that, “depending on a number of factors,” a product approved as an interchangeable biosimilar may have as much as a year’s exclusivity, Wong said.
Also last week, the FDA approved an insulin glargine (Semglee) under the 505(b)(2) pathway. The drug automatically is deemed approved under section 351(a) of the Public Health Service Act of the Biologics Price Competition and Innovation Act. For the full story, click here.
Partnering for Biosimilar Security: India's Role in US Health Care Savings, Supply Chain Stability
May 9th 2024As Indian pharmaceutical companies supplied 4 of every 10 prescriptions in the US in 2022, generating $1.3 trillion in health care savings, a new IQVIA report highlights concerns about supply chain risks and advocates for partnerships to bolster biosimilar security and overall supply chain resilience.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Eye on Pharma: EU Ustekinumab Approval; New Golimumab Data; Evernorth Adds Humira Biosimilar
April 29th 2024The European Union gained a new ustekinumab biosimilar; Alvotech released positive results from a clinical trial evaluating a golimumab biosimilar and the reference products (Simponi and Simponi Aria), and Evernorth announced that it is set to cover an adalimumab biosimilar at zero cost to patients.